Acute Hepatic Porphyria clinical trials at UCSF
1 in progress, 0 open to new patients

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).